Background Sarcopenia is the progressive generalized loss of skeletal muscle mass, strength, and function that occurs with aging. This study was undertaken to identify new biomarkers of sarcopenia by proteomics analysis of female sera. Methods A case-control study was set up, for which 19 sarcopenic subjects and 20 control subjects, according to the European Working Group on Sarcopenia Older People criteria published in 2010 (EWGSOP1), were enrolled. All the subjects were at least 65 years old and in majority female. Biomarker screening was performed by a comparative mass spectrometry analysis. Protein expression levels between the two groups were compared. One of the identified biomarkers, cathepsin D, was measured by immunoassay on the serum of the full sample set (n = 39). Its diagnostic performance was evaluated with a receiver operating characteristic curve (ROC curve). Results Two biomarkers were identified: fructose-biphosphate aldolase A (P ≤ 0.05) and cathepsin D (P ≤ 0.05). The levels of all of them were higher in sarcopenic patients. It was confirmed by immunoassay that cathepsin D levels in serum were significantly higher in the sarcopenic group of patients (P = 0.038). An inverse correlation (À0.385) was observed between cathepsin D levels in serum and gait speed. The area under the ROC curve measurement (AUC = 0.696) demonstrated that cathepsin D levels could discriminate between sarcopenic and non-sarcopenic subjects. A predictive model including cathepsin D, age, and body mass index was established to improve the diagnostic performance (AUC = 0.908). Conclusions Cathepsin D has been identified as a diagnostic biomarker of sarcopenia.
Purpose: Coll2-1 is a nine amino acid sequence (HRGYPGLDG) specific of type II collagen which is released during cartilage degradation. This peptide is located in the triple helicoidal part of type II collagen molecule. This study aims to assess intra-individual biological variability of serum cartilage specific biomarker Coll2-1 and define the best standardized conditions for blood sampling in clinical trials. Methods: Blood samples were taken from 122 subjects with diagnosed knee osteoarthritis (KOA) at a single timepoint as well as from 15 healthy subjects under various conditions, including fasting condition (before or after breakfast and lunch), sampling time (at 8am, 9am, 12pm, 2pm and 5pm), sampling season (at baseline and after 2, 16, 52 and 68 weeks), physical activity (after a resting weekend versus working day), blood treatment (blood clotting from 1h to 24h at room temperature or 4 C; centrifugation at room temperature or 4 C) and type of blood collection tube (dry tube versus dry tube with gel separator). Type II collagen-specific biomarker Coll2-1 was measured using ELISA (Artialis Groups SA, Li ege, Belgium) on all collected samples. Results: There was no significant difference on Coll2-1 values between samples collected at any of the five sampling times (p¼0.85) or at any of the sampling days measured (p¼0.58). None of the sampling parameters tested had a significant impact on Coll2-1 value (clotting time, clotting temperature and temperature of blood centrifugation (p¼0.93), type of tube: p¼0.38) when all data from healthy subjects were pooled (n¼631 samples). On the contrary,subjects with knee OA had a significantly higher Coll2-1 concentration then healthy subjects (p<0,001). Conclusions: Coll2-1 is a biomarker of osteoarthritis measured using an immunoassay sufficiently robust for use in OA clinical trials. Coll2-1 measurement is not affected by subject specific conditions such as fasting, resting state, circadian rhythm, seasonality, nor by sampling process factors such as type of dry tube, clotting patterns and centrifugation temperature.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.